Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of the directed movement of L-glutamate into a neuron or glial cell. [GOC:ai]
Glutamate uptake is a crucial process in regulating neuronal signaling and maintaining brain function. Here's a detailed explanation of its biological process:
**1. Glutamate Release and Synaptic Transmission:**
* Neurons communicate with each other via synapses, specialized junctions where neurotransmitters are released. Glutamate is the primary excitatory neurotransmitter in the central nervous system.
* When an action potential arrives at the presynaptic terminal, voltage-gated calcium channels open.
* Calcium influx triggers the fusion of synaptic vesicles containing glutamate with the presynaptic membrane.
* Glutamate is released into the synaptic cleft, the narrow space between the presynaptic and postsynaptic neurons.
**2. Glutamate Binding and Postsynaptic Activation:**
* Glutamate molecules bind to specific receptors on the postsynaptic membrane.
* These receptors are classified into two major types: ionotropic receptors (NMDA and AMPA receptors) and metabotropic receptors (mGluRs).
* Binding of glutamate to ionotropic receptors opens ion channels, allowing the influx of sodium and calcium ions, leading to depolarization of the postsynaptic neuron and the initiation of a new action potential.
* Metabotropic receptors activate intracellular signaling pathways, influencing neuronal excitability and plasticity.
**3. Glutamate Uptake and Termination of Signaling:**
* Glutamate must be rapidly removed from the synaptic cleft to prevent overstimulation and excitotoxicity.
* This removal is primarily achieved through the action of glutamate transporters, specialized proteins located on the membranes of neurons and glial cells (astrocytes).
* These transporters actively transport glutamate from the synaptic cleft back into the presynaptic terminal or into astrocytes.
* The energy for this transport is provided by the sodium gradient maintained by the sodium-potassium pump.
* Once re-uptaken, glutamate can be recycled into synaptic vesicles for future release or metabolized.
**4. Regulation of Glutamate Uptake:**
* Glutamate uptake is tightly regulated to ensure proper synaptic function.
* Factors influencing uptake include:
* **Glutamate concentration:** Higher glutamate levels lead to increased uptake.
* **Transporter expression:** The number of glutamate transporters on the cell membrane can be regulated.
* **Modulatory molecules:** Various substances, such as neurosteroids and drugs, can influence transporter activity.
* **Cellular energy levels:** ATP depletion can impair transporter function.
**5. Importance of Glutamate Uptake:**
* Efficient glutamate uptake is essential for maintaining normal brain function.
* It prevents excitotoxicity, a potentially harmful process where excessive glutamate levels can lead to neuronal death.
* It ensures precise temporal control of synaptic transmission.
* It contributes to synaptic plasticity, the ability of synapses to change their strength over time.
**6. Dysregulation of Glutamate Uptake and Neurological Disorders:**
* Dysregulation of glutamate uptake can contribute to various neurological disorders, including:
* **Epilepsy:** Seizures are often associated with excessive glutamate release and impaired uptake.
* **Alzheimer's disease:** Glutamate dysregulation is implicated in neuronal damage and cognitive decline.
* **Stroke:** Ischemic stroke can lead to excessive glutamate release and excitotoxicity.
* **Schizophrenia:** Glutamate signaling abnormalities are thought to contribute to the disorder.
**7. Therapeutic Implications:**
* Understanding the regulation of glutamate uptake has led to the development of drugs targeting glutamate transporters.
* These drugs are used to treat a range of neurological conditions, including epilepsy, stroke, and neurodegenerative disorders.
* By modulating glutamate uptake, these drugs can help restore balance to neuronal signaling and improve brain function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Sodium/potassium-transporting ATPase subunit alpha-2 | A sodium/potassium-transporting ATPase subunit alpha-2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P50993] | Homo sapiens (human) |
Period circadian protein homolog 2 | A period circadian protein homolog 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O15055] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
lansoprazole | Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
omeprazole | 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole. Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
pantoprazole | pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER. | aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic |
digoxigenin | digoxigenin : A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3beta-, 12beta- and 14beta-positions. It has been isolated from the plant species of the genus Digitalis. Digoxigenin: 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide. A cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh. | 12beta-hydroxy steroid; 14beta-hydroxy steroid; 3beta-hydroxy steroid; 3beta-sterol | hapten; plant metabolite |
digoxigenin-bis(digitoxoside) | cardenolide glycoside | ||
rostafuroxin | rostafuroxin: structure in first source | ||
ouabain | cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus. Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. | 11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone | anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite |
digitoxin | digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor |
digoxin | digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) | cardenolide glycoside; steroid saponin | anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope |
kl001 | KL001: inhibits degradation of the cryptochrome; structure in first source | ||
digitoxigenin | digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22). Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin. | 14beta-hydroxy steroid; 3beta-hydroxy steroid | |
phakellistatin 2 | phakellistatin 2: isolated from the marine sponge Phakellia carteri; structure in first source | ||
digitoxigenin monodigitoxoside | digitoxigenin monodigitoxoside: RN given refers to (ribo-3beta,5beta)-isomer | ||
evomonoside | evomonoside : A cardenolide glycoside consisting of digitoxigenin having an alpha-L-rhamnosyl moiety attached at the O(3)-position. evomonoside: a cytotoxic cardiac glycoside from Lepidium apetalum; RN refers to (3beta,5beta)-isomer | cardenolide glycoside | |
halisulfate 1 | halisulfate 1: an isocitrate lyase inhibitor sesterterpene sulfate from sponge, Hippospongia sp.; structure in first source | organic molecular entity | metabolite |